The ALS Therapy Development Institute (ALS TDI) is proud to announce that the first participant was successfully given a dose of AT-1501 in the first clinical trial of the experimental treatment for amyotrophic lateral sclerosis (ALS). The phase 1 safety trial is enrolling healthy volunteers and people living with ALS, following the acceptance of an Investigational New Drug (IND) application by the Food & Drug Administration (FDA). A total of 8 people living with ALS will receive AT-1501 in this study, with the aim of determining safety and tolerability of the experimental antibody. The trial, sponsored by Anelixis Therapeutics, LLC, will also determine the pharmacokinetics of AT-1501, i.e. how the drug acts within the body.
Did you ever stop to think about how water can move? Or think about how people can move as well? I’m not talking about specific actions, but just the basic ability. But there’s a caveat that many people forget: those with ALS lose the natural ability to move as their motor neurons die and their muscles cease functioning.
When the ALS Therapy Development Institute invited me to speak at their annual White Coat Affair gala last October, I took advantage of the opportunity to tour the Institute’s lab where they are performing fast-track ALS research. While there, our tour passed by the freezer where AT-1501, a potential effective treatment for both ALS and Alzheimer’s, is stored.